

Press Release

ProStrakan Group plc

Peter Allen takes up position as Chairman of ProStrakan.

Galashiels, Scotland, 7th December, 2007 – ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, announced on 30th October, 2007 that its co-founder and Chairman, Harry Stratford OBE, had informed the Board of his intention to retire as Chairman at the end of 2007. The Company also announced that Peter Allen, a Non-Executive Director since 2005, had accepted the Board's invitation to replace him.

ProStrakan announces that the formal handover took place at the Company's Board meeting which was held yesterday (6th December, 2007).

Further enquiries:

ProStrakan

Callum Spreng, Corporate Comms Director

Tel: +44 (0) 1896 664000

Financial Dynamics

Ben Brewerton

Tel: +44 (0) 20 7831 3113

Notes to Editors:

ProStrakan

ProStrakan Group plc is a rapidly growing international specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office and development facilities are situated in Galashiels in Scotland. EU-wide sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, France, Germany, Spain and other EU countries. The company has recently announced its expansion into the US. www.prostrakan.com

Harry Stratford OBE

Harry Stratford co-founded ProStrakan in 1995 and was CEO of the Company until his appointment as Executive Chairman in 2004. In 2006 he became Non-Executive Chairman of the Group. Harry is a founder and former CEO of Shire Pharmaceuticals. He has extensive experience of the pharmaceutical industry spanning over 30 years. He was awarded an OBE in the 2007 New Year's Honours List for his contribution to the Scottish Life Sciences industry.

Peter Allen

Peter Allen ACA was CFO and Deputy CEO of Celltech Group plc between 1992 and 2004. In addition to managing the company's flotation process in 1993, leading to a listing on the London Stock Exchange, Peter played a key role in several strategic acquisitions, including Chiroscience, Medeva and Oxford Glycosciences. In May 2004, Peter was a key participant in the sale of Celltech to UCB. Prior to this, he was Group Financial Controller of Associated British Ports Holdings plc and Financial Controller with L'Oreal (UK) Ltd. In April 2005, he was appointed CFO of Abacus Group plc, the quoted electronics distributor.